Pipeline

凡例

当社最重要パイプライン Basic Research 非臨床試験 第Ⅰ相臨床試験
NC-6004
VB-111
NC-6300/K-912
NC-4016
NC-6201 ADCM-E7974
Active-NanoFect
NK105
Regarding NK105, Nippon Kayaku Co., Ltd., to which we granted the license,is planning an additional clinical trial of PIII for breast cancer,according to the presentation material of financial results for the third quarter of the fiscal year ending March 31, 2017, which was released on January 31,2017.